Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes
Sponsor: Hoffmann-La Roche
Summary
This study will evaluate the efficacy and safety of petrelintide compared with placebo, in conjunction with a reduced-calorie diet and increased physical activity, for weight management in participants living with overweight or obesity and with Type 2 Diabetes (T2D).
Official title: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once Weekly Petrelintide vs. Placebo in Participants With Overweight or Obesity and Type 2 Diabetes
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
600
Start Date
2026-09-30
Completion Date
2029-01-19
Last Updated
2026-10-07
Healthy Volunteers
No
Conditions
Interventions
Petrelintide
Petrelintide will be administered subcutaneously (SC) using a drug-device combination product.
Placebo
Petrelintide-matching placebo will be administered SC using a drug-device combination product.
Locations (2)
Institute for Metabolic Research Los Angeles
Los Angeles, California, United States
Manassas Clinical Research Center
Manassas, Virginia, United States